Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

How Compass is developedGive feedback

A new statistical method was illustrated using data from an amyotrophic lateral sclerosis trial

Original source

Randomization-based covariance analysis for hypothesis testing of treatment comparisons based on restricted mean survival time with categorized time-to-event data.J Biopharm Stat · 5 August 2026 (opens in a new tab)

Compass summarised this from the study's abstract.

Study details

Studied in
Human

Population inferred from the title and abstract by Compass.

Article

View article on the publisher's site (opens in a new tab)via the publisher — full text availability varies

Researchers introduced a randomization-based analysis of covariance method for comparing restricted mean survival time between treatments in randomized trials. The method adjusts for baseline covariates and can analyse categorized time-to-event data without assuming proportional hazards. It was illustrated with data from a randomized, placebo-controlled trial of a test treatment for amyotrophic lateral sclerosis.

Why this matters

The approach could help researchers assess treatment differences in survival-related outcomes while accounting for baseline differences between trial groups. This is a statistical method, not evidence that the illustrated treatment benefited people with amyotrophic lateral sclerosis, and it does not change treatment for patients now.

Limitations and context

This source reports a methods paper, not a new clinical efficacy result. The treatment-trial data are used as an illustration, and the source does not report a treatment benefit in people with amyotrophic lateral sclerosis. The method's performance and clinical usefulness would still need assessment across relevant trials and datasets.

Summarised by Compass 8 August 2026

This summary was generated by AI from the source listed above. It is not medical advice, so read the original source for anything that affects your care.

Bibliographic data from PubMed is courtesy of the U.S. National Library of Medicine. Compass does not reproduce source abstracts and may not reflect the most current record.

Relevant to you?